p.114 抽出テキスト

256. Watson NF, Bushnell T, Jones TK, et al. A novel method for the evaluation and treatment of obstructive sleep apnea in four adults with complex congenital heart disease and Fontan repairs. Sleep Breath 2009; 13: 421-424. PMID: 19449048 257. Cordina RL, O’Meagher S, Karmali A, et al. Resistance training improves cardiac output, exercise capacity and tolerance to positive airway pressure in Fontan physiology. Int J Cardiol 2013; 168: 780- 788. PMID: 23154055 258. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002; 105: 438-445. PMID: 11815425 259. Stanton T, Hawkins NM, Hogg KJ, et al. How should we optimize cardiac resynchronization therapy? Eur Heart J 2008; 29: 2458- 2472. PMID: 18755703 260. Auricchio A, Fantoni C, Steinberg JS. Acute and chronic sequelae of ventricular dyssynchrony. Prog Cardiovasc Dis 2006; 48: 227- 231. PMID: 16517244 261. Bertini M, Delgado V, Bax JJ, et al. Why, how and when do we need to optimize the setting of cardiac resynchronization therapy? Europace 2009; 11 Suppl: v46-v57. PMID: 19861391 262. Ishikawa T, Sumita S, Kimura K, et al. Prediction of optimal atrioventricular delay in patients with implanted DDD pacemakers. Pacing Clin Electrophysiol 1999; 22: 1365-1371. PMID: 10527018 263. Miyazaki A, Yoshimura SI, Matsutani H, et al. Extremely short setting of optimal sensed atrioventricular interval in patients after Fontan procedure with implanted dual-chamber pacemaker. Cardiol Young 2019; 29: 1375-1379. PMID: 31507257 264. Yin Y, Dimopoulos K, Shimada E, et al. Early and Late Effects of Cardiac Resynchronization Therapy in Adult Congenital Heart Disease. J Am Heart Assoc 2019; 8: e012744. PMID: 31657270 265. Miyazaki A, Sakaguchi H, Kagisaki K, et al. Optimal pacing sites for cardiac resynchronization therapy for patients with a systemic right ventricle with or without a rudimentary left ventricle. Europace 2016; 18: 100-112. PMID: 25745073 266. Janoušek J, Kovanda J, Ložek M, et al. Pulmonary Right Ventricular Resynchronization in Congenital Heart Disease: Acute Improvement in Right Ventricular Mechanics and Contraction Efficiency. Circ Cardiovasc Imaging 2017; 10: e006424. PMID: 28877886 267. Moore JP, Cho D, Lin JP, et al. Implantation techniques and outcomes after cardiac resynchronization therapy for congenitally corrected transposition of the great arteries. Heart Rhythm 2018; 15: 1808-1815. PMID: 30125719 268. Thambo JB, De Guillebon M, Xhaet O, et al. Biventricular pacing in patients with Tetralogy of Fallot: Non-invasive epicardial mapping and clinical impact. Int J Cardiol 2013; 163: 170-174. PMID: 21807429 269. Higaki T, Kondo C, Tomimatsu H, et al. Asynchronous contraction of the 2 ventricles caused by ventricular pacing after a Fontan-type operation in a patient with a biventricular heart. Int J Cardiol 2011; 150: e116-e118. PMID: 20226550 270. Miyazaki A, Sakaguchi H, Noritake K, et al. Interventricular dyssynchrony in a patient with a biventricular physiology and a systemic right ventricle. Heart Vessels 2017; 32: 234-239. PMID: 27385023 271. Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009; 95: 1165-1171. PMID: 19307198 272. Cecchin F, Frangini PA, Brown DW, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: Five years experience in a single institution. J Cardiovasc Electrophysiol 2009; 20: 58-65. PMID: 18775051 273. Hayama Y, Miyazaki A, Ohuchi H, et al. Septal Flash-like Motion of the Earlier Activated Ventricular Wall Represents the Pathophysiology of Mechanical Dyssynchrony in Single-Ventricle Anatomy. J Am Soc Echocardiogr 2020; 33: 612-621. PMID: 32089381 274. Fratz S, Hager A, Busch R, et al. Patients after atrial switch operation for transposition of the great arteries can not increase stroke volume under dobutamine stress as opposed to patients with congenitally corrected transposition. Circ J 2008; 72: 1130-1135. PMID: 18577823 275. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. PMID: 30545968 276. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-D41. PMID: 24355639 277. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958; 2: 755-762. PMID: 13572894 278. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt

lesions: a critical review. Pulm Circ 2020; 10: 1–9. PMID: 32313642 279. Bradley EA, Ammash N, Martinez SC, et al. “Treat-to-close”: Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry. Int J Cardiol 2019; 291: 127-133. PMID: 31031077 280. Yao A. “Treat-and-Repair” Strategy for Atrial Septal Defect and Associated Pulmonary Arterial Hypertension. Circ J 2016; 80: 69-71. PMID: 26638873 281. Hu Z, Xie B, Zhai X, et al. Midterm results of “treat and repair” for adults with non-restrictive ventricular septal defect and severe pulmonary hypertension. J Thorac Dis 2015; 7: 1165-1173. PMID: 26380732 282. Tamura Y, Kumamaru H, Satoh T, et al. Japan PH Registry (JAPHR) Network. Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J 2017; 82: 275-282. PMID: 28747612 283. Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014; 118: 414-419. PMID: 24530872 284. Yamaki S. Pulmonary vascular disease associated with pulmonary hypertension in 445 patients: diagnosis from lung biopsy and autopsy. Gen Thorac Cardiovasc Surg 2013; 61: 24-31. PMID: 23011519 285. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005; 24: 1174-1176. PMID: 16102469 286. Ishida H, Kogaki S, Ichimori H, et al. Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients. Int J Cardiol 2012; 159: 34-39. PMID: 21356562 287. Yamagishi M, Kurosawa H, Hashimoto K, et al. The role of plasma endothelin in the Fontan circulation. J Cardiovasc Surg (Torino) 2002; 43: 793-797. PMID: 12483168 288. Khambadkone S, Li J, de Leval MR, et al. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003; 107: 3204-3208. PMID: 12821557 289. Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: A randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123: 1185-1193. PMID: 21382896 290. Mori H, Park IS, Yamagishi H, et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122-127. PMID: 27400308 291. Hill KD, Maharaj AR, Li JS, et al. A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery. Pediatr Crit Care Med 2020; 21: e795-e803. PMID: 32639468 292. Agnoletti G, Gala S, Ferroni F, et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg 2017; 153: 1468-1475. PMID: 28283234 293. 八尾厚史,相馬桂,稲葉俊郎.心房中隔欠損シャント性肺動脈性肺高血圧に対するTreat and Repair の適用.日成人先天性心疾患会誌 2019;8:12-24. 294. Ogawa A, Satoh T, Tamura Y, et al. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. Am J Cardiol 2017; 119: 1479-1484. PMID: 28267959 295. Fujino T, Yao A, Hatano M, et al. Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension. Int Heart J 2015; 56: 86-93. PMID: 25742945 296. Levy M, Del Cerro MJ, Nadaud S, et al. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol 2018; 264: 153-157. PMID: 29650343 297. López-Medrano F, Fernández-Ruiz M, Ruiz-Cano MJ, et al. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. [Article in English, Spanish] Arch Bronconeumol 2012; 48: 443-447. PMID: 22858303 298. Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc 2012; 87: 825-834. PMID: 22883740 299. Centers for Disease Control and Prevention (CDC). Bloodstream in-

fections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven